5 months ago

BioSapien Extends Pre-Series A to $7M for Localized Cancer Treatment

  • BioSapien, a UAE-based biotech company, extended its pre-Series A funding round to $7 million

  • The funding includes a strategic investment from Golden Gate Ventures (through its MENA Fund) and will accelerate clinical trials for MediChip™, BioSapien's 3D-printed drug delivery platform, in the UAE

  • The investment highlights the UAE's growing prominence in healthcare innovation.

      • ProblemHealthcare

      "Current cancer treatments, like systemic chemotherapy, often cause severe side effects due to the medication affecting the whole body, not just the tumor. This can significantly impact a patient's quality of life."

      Solution

      "MediChip™ is a 3D-printed, slow-release drug delivery platform that delivers medication directly to the tumor, minimizing side effects by targeting only the cancerous cells. This allows for more effective treatment with lower drug dosages."

      Covered on